Immune checkpoint inhibitor-associated nephritis - treatment standard

医学 急性肾损伤 中止 狼疮性肾炎 内科学 不利影响 肾炎 重症监护医学 肿瘤科 疾病
作者
Elena-Bianca Barbir,Abhijat Kitchlu,Sandra M. Herrmann
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
标识
DOI:10.1093/ndt/gfae184
摘要

Abstract Over the last 13 years, the use of immune checkpoint inhibitor (ICI) therapy has grown remarkably, owing to their unprecedented anti-tumor efficacy in certain tumor groups. With increased use of ICIs, we are seeing immune-related adverse events (irAE's) more frequently. Renal irAE's, such as ICI-associated acute kidney injury (ICI-AKI), are reported in 2–5% of patients treated with ICIs, with acute tubulointerstitial nephritis (ATIN) as the most common histopathologic lesion, though various forms of glomerulonephritis have also been reported. Modifiable risk factors for ICI-AKI include concurrent use of ATIN-associated drugs, like proton pump inhibitors, non-steroidal anti-inflammatory drugs and antibiotics, and dual ICI therapy with both CTLA-4 and PD1/PDL-1 blockade. Kidney biopsies remain the diagnostic modality of choice, though several promising non-invasive biomarkers, which have not yet been broadly clinically validated have emerged. The treatment of ICI-AKI involves holding ICIs, discontinuation of ATIN-associated drugs, and initiation of immunosuppression with corticosteroids as first-line therapy. With prompt treatment initiation, most patients achieve full or partial renal recovery, allowing for re-challenge with ICI. However, a subset of patients will require additional steroid-sparing therapies for corticosteroid-dependent or refractory ICI-AKI. Here we review developments in our understanding of the pathophysiology of ICI-AKI, the approach to diagnosis (with a focus on the emergence of novel diagnostic tools), prognostic factors and the current evidence for establishing treatment standards for ICI-AKI. As the evidence base remains largely retrospective, we identify questions that would benefit from future prospective studies in the diagnosis, management, and prognostication of ICI-AKI.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助曹姗采纳,获得10
1秒前
1秒前
2秒前
葡萄成熟应助科研通管家采纳,获得10
3秒前
今后应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
咖啡豆应助科研通管家采纳,获得20
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
英姑应助科研通管家采纳,获得10
4秒前
英姑应助科研通管家采纳,获得10
4秒前
完美世界应助科研通管家采纳,获得10
4秒前
华仔应助科研通管家采纳,获得10
4秒前
lixiao应助科研通管家采纳,获得10
4秒前
上官若男应助科研通管家采纳,获得10
4秒前
咖啡豆应助科研通管家采纳,获得20
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
4秒前
正增长发布了新的文献求助20
4秒前
zzz发布了新的文献求助30
8秒前
11秒前
打打应助白佐帅采纳,获得10
14秒前
tuanheqi应助kento采纳,获得50
15秒前
17秒前
tefy完成签到,获得积分10
19秒前
20秒前
大个应助小混分怪采纳,获得10
21秒前
安静的虔发布了新的文献求助10
22秒前
粗暴的遥发布了新的文献求助10
23秒前
你好呀嘻嘻完成签到 ,获得积分10
23秒前
MZ完成签到,获得积分10
24秒前
香蕉觅云应助程克勤采纳,获得10
24秒前
画舫发布了新的文献求助10
25秒前
25秒前
33完成签到 ,获得积分10
28秒前
28秒前
神凰完成签到,获得积分10
30秒前
小蘑菇应助zhangzhenfei采纳,获得10
30秒前
31秒前
微笑二娘完成签到 ,获得积分10
31秒前
小蘑菇应助云鲲采纳,获得10
33秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
Case Research: The Case Writing Process 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141402
求助须知:如何正确求助?哪些是违规求助? 2792438
关于积分的说明 7802634
捐赠科研通 2448628
什么是DOI,文献DOI怎么找? 1302644
科研通“疑难数据库(出版商)”最低求助积分说明 626650
版权声明 601237